RXRX RECURSION PHARMACEUTICALS INC

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results

SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later this afternoon as previously stated. The corrected bullet should have read:

  • L(earnings) Call: We will host a L(earnings) Call on Aug 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time. We will broadcast the live stream from Recursion’s X (formerly Twitter), LinkedIn, and YouTube accounts and there will be opportunities to ask questions of the company.

The rest of the release remains unchanged.

Media Contact

Investor Contact



EN
08/08/2024

Underlying

RXRXRECURSION PHARMACEUTICALS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates...

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026, before the open of the financial markets. Recursion will host a (L)ear...

February 18, 2026 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasda...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award w...

February 12, 2026 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will also participate in the following upcoming investor conference: 28th Annual Needham Growth Conference - Friday, January 16, 2026 Webcasts may be found in th...

January 6, 2026 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonst...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of unt...

December 8, 2025 1 EN
 PRESS RELEASE
Free
RXRX RECURSION PHARM...

Recursion Announces Webinar For Upcoming Clinical Data Readout on the ...

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recurs...

December 1, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch